Octreotide followed by injection sclerotherapy
| Outcome | Octreotide | Sclerotherapy | RRR1-1-150(95% CI) | NNT1-1-151 |
| Rebleeding at 48 h | 15% | 18% | 17% (−68 to 59) | NS1-1-152 |
| Outcome | Octreotide | Sclerotherapy | RRI1-1-153 (CI) | NNH1-1-154 |
| Deaths at 60 days1-1-160 | 32% | 17% | 91% (−3 to 278) | NS |
| Complications | 26% | 19% | 34% (−26 to 141) | NS |
↵1-1-150 RRR=relative risk reduction (the proportional reduction in rates of bad events between the octreotide and sclerotherapy groups); calculated from data in article.
↵1-1-151 NNT=number needed to treat (the number of patients who need to be treated with octreotide to achieve 1 additional favourable outcome); calculated from data in article.
↵1-1-152 NS=not significant.
↵1-1-153 RRI=relative risk increase (the proportional increase in rates of bad events between the octreotide and sclerotherapy groups); calculated from data in article.
↵1-1-154 NNH=number of patients who, if they received octreotide, would lead to 1 additional adverse outcome; calculated from data in article.
↵1-1-160 RRI and CI abstracted from article which used the Cox proportional hazards model.